Ozempic maker warns doctors against writing compounded scripts due to ‘potential safety risks’
In the US, Novo Nordisk has sued compounding pharmacists.
Semaglutide maker Novo Nordisk has hit back at GPs prescribing compounded versions of its blockbuster drug.
Semaglutide (Ozempic) was already under scrutiny for mass off-label prescribing as a weight loss treatment before telehealth corporate Eucalyptus announced its GPs were prescribing a locally compounded version.
Novo Nordisk has now issued a warning over off-label prescribing and pharmacy compounding.
“We do not, and will not support any type of non-indicated (off-label) use of a Novo Nordisk product at any time,” the company said in a statement to AusDoc.
